Effect of 6-azacytidine on the course of experimental adenoviral infection in newborn Syrian hamsters

Journal of Chemotherapy

Volumn 19, Issue 1, 2007, Pages 44-51

  Zarubaev, Vladimir V ^a   Slita, A V ^a   Sukhinin, V P ^a   Nosach, L N ^b   Dyachenko, N S ^b   Povnitsa, O Y ^b   Zhovnovataya, V L ^b   Alexeeva, I V ^c   Palchikovskaya, L I ^c  

^a Influenza Research Institute   (Russian Federation)

^b ZABOLOTNY INSTITUTE OF MICROBIOLOGY AND VIROLOGY   (Ukraine)

^c INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

Author keywords

6 azacytidine; Adenovirus; Animal model; Antiviral compounds; Chemotherapy; Viral infection

Indexed keywords

6 AZACYTIDINE;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL DESTRUCTION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG SELECTIVITY; DRUG STRUCTURE; EXPERIMENTAL INFECTION; HEART; HEP 2 CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; KIDNEY; LIVER; LUNG; NEWBORN; NONHUMAN; SPLEEN CELL; SYRIAN HAMSTER; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TITRATION;

EID: 33846986785     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.1.44     Document Type: Article

References (37)

1. Bailey A, Mautner V. Phylogenic relationships among adenovirus serotypes. Virology 1994;205 (2): 438-452.
2. Naesens L, Lenaerts L, Andrei G, et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 2005; 49 (3): 1010-1016.
3. La Rosa AM, Champlin RE, Mirza M, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32 (6): 871-876.
4. Das A, Trousdale MD, Ren S, Lien EJ. Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate. Antiviral Res 1999; 44 (3):201-208.
5. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res 1987; 8 (5-6): 261-272.
6. Arav-Boger R, Echavarria M, Forman M, Charache P, Persaud D. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr Infect Dis J 2000; 19 (11): 1097-1100.
7. Shetty AK, Gans HA, So S, Millan MT, Arvin AM, Gutierrez KM, Intravenous ribavirin therapy for adenovirus pneumonia. Pediatr Pulmonol 2000; 29 (1): 69-73.
8. Gavin PJ, Katz BZ. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 2002; 110 (1 pt 1): 1-8.
9. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32 (9): 1290-1297.
10. Trousdale MD, Goldschmidt PL, Nobrega R. Evaluation of Ganciclovir against human adenovirus type 5 infection in cell culture and cotton rat eyes. Antiviral Res 1993; 20 suppl. 1: 48.
11. Chen FE, Liang RH, Lo JY, Yuen KY, Chan TK, Peiris M. Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant 1997; 20 (11): 997-999.
12. Hillenkamp J, Reinhard T, Ross RS, et al. The effect of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 2002; 109 (5): 845-850.
13. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7 (7): 388-394.
14. Romanowski EG, Yates KA, Gordon YJ. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res 2001; 52 (3): 275-280.
15. Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kirichington PR. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand white rabbit ocular model. Invest Ophthalmol Vis Sci 2001; 42 (8): 1812-1815.
16. Safrin S, Cherrington J, Jaffe HS. Cidofovir. Review of current and potential clinical uses. Adv Exp Med Biol 1999;458: 111-120.
17. Hitchcock MJM, Jaffe HS, Martin JC, Stagg RJ. Cidofovir, a new agent with potent anti-herpesvirus activity. Antivir Chem Chemother 1996;7 (3): 115-127.
18. Gordon YJ, Naesens L, De Clercq E, Maudgal PC, Veckeneer M. The treatment of adenoviral conjunctivitis with topical cidofovir. Cornea. 1996; 15 (5): 546.
19. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324 (6):342-344.
20. Gordon YJ, Araullo-Cruz TP, Johnson YP, Romanowski EG, Kinchington PR. Isolation of human adenovirus type 5 variants resistant to the antiviral Cidofovir. Invest Ophthalmol Vis Sci 1996; 37 (13): 2774-2778.
21. 3 against adenovirus in vitro. Antiviral Res 2001; 52 (3): 281-288.
22. Zarubaev VV, Slita AV, Krivitskaya VZ, Sirotkin AK, Kovalenko AL, Chatterjee NK. Direct antiviral effect of cycloferon (10-carboxymethyl-9- acridanone) against adenovirus type 6 in vitro. Antiviral Res 2003; 58 (2):131-137.
23. Rautenschlein S, Miller RL, Sharma JM. The inhibitory effect of the imidazoquinolinamine S-28828 on the pathogenesis of a type II adenovirus in turkeys. Antiviral Res 2000;46 (3):195-205.
24. Mentel R, Kinder M, Wegner U, Janta-Lipinski M, Matthes E. Inhibitory activity of 3-fluoro-2-deoxythymidine and related nucleoside analogues against adenoviruses in vitrî. Antiviral Res 1997; 34 (3): 113-119.
25. Weber JM, Ruzindana-Umunyana A, Imbeault L, Sircar S. Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res 2003; 58 (2): 167-173.
26. Alexeeva IV, Dyachenko NS, Nosach LN, et al. 6-Azacytidine -compound with wide spectrum of antiviral activity. Nucleosides Nucleotides & Nucleic Acids 2001; 20 (4-7): 1147-1152.
27. Alexeeva IV, Palchikovskaya LI, Shalamay A, et al. N-4-Amino-acid derivatives of 6-azacytidine: structure-activity relationship. Acta Biochim Polon 2000; 47 (1): 95-101.
28. Vorbruggen H, Bennua B. Nucleoside synthesis. XXV. A new simple nucleoside synthesis. Chem. Ber 1981;144:1279-1286.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65 (1-2):55-63.
30. Puvion-Dutilleul F, Pudron J, Cajean-Feroldi C. Identification of intranuclear structures containing the 72K DNA-binding protein of human adenovirus type 5. Eur J Cell Biol 1984; 34 (2): 313-322.
31. Betts AO, Jennings AR, Zamont PH, Page Z. Inoculation of pigs with adenovirus of human origin. Nature 1962; 193 (4851): 45-46.
32. Pereira HG, Allison AC, Niven JS. Fatal infection îf newborn hamsters by an adenovirus of human origin. Nature 1962; 196: 244-245.
33. Hayder H, Blanden R, Körner H, Riminton DS, Sedgwick JD, Müllbacher A. Adenovirus-induced liver pathology is mediated through TNF receptors I and II but is independent of TNF of lymphotoxin. J Immunol 1999; 163 (3): 1516-1520.
34. Gordon YJ, Romanowski E, Araullo-Cruz T. An ocular model of adenovirus type 5 infection in the NZ rabbit. Invest Ophthalmol Vis Sci. 1992; 33 (3):574-580.
35. Galushko SV, Shishkina NP. Reversed-phase ion-paired high-performance liquid chromatographic determination of 6-azacytidine in blood. Chromatography 1985;345 (1): 157-161.
36. Curran M, Noble S. Valganciclovir. Drugs 2001; 61 (8):1145-1150.
37. Hösel M, Schroer J, Webb D, Jaroshevskaja E, Doerfler W. Cellular and early viral factors in the interaction of adenovirus type 12 with hamster cells: the abortive response. Virus Res 2001; 81 (1-2):1-16.